By Blake Brittain

作者：Blake Brittain

Aug 21 (Reuters) - A Delaware federal jury determined on Friday that Cytek Biosciences’ (CTKB.O) products for analyzing single-cell blood and tissue samples infringe a patent owned by rival Beckman Coulter.

8 月 21 日（路透社）- 特拉华州联邦陪审团周五裁定，Cytek Biosciences (CTKB.O) 用于分析单细胞血液和组织样本的产品侵犯了竞争对手贝克曼库尔特拥有的一项专利。

The jury agreed with Danaher-owned (DHR.N) Beckman that Cytek’s Aurora flow cytometers and other products violate Beckman’s patent rights in technology used in its competing CytoFLEX platform.

陪审团认同丹纳赫 (DHR.N) 旗下贝克曼的观点，即 Cytek 的 Aurora 流式细胞仪及其他产品侵犯了贝克曼在其竞争性平台 CytoFLEX 所用技术方面的专利权。

The jury said that Cytek owed Beckman $36 million in royalties and $20 million in lost profits.

陪审团表示，Cytek 需向贝克曼支付 3,600 万美元的特许权使用费和 2,000 万美元的利润损失。

Spokespeople for the companies did not immediately respond to requests for comment on the verdict.

两家公司发言人未立即回应置评请求。

Beckman first sued Cytek over the patents in 2024.

贝克曼于 2024 年首次就这些专利起诉 Cytek。

Cytek denied the allegations and argued the patents were invalid.

Cytek 否认了相关指控，并主张这些专利无效。

The jury found on Thursday that Cytek did not infringe two of the three patents at issue in the trial and that those two patents were invalid.

陪审团周四认定，Cytek 并未侵犯庭审中涉及的三项专利中的两项，且该两项专利无效。

California-based Cytek earned $201.5 million from overall sales of its products last year, according to a company report.

根据公司报告，总部位于加利福尼亚州的 Cytek 去年产品总销售额为 2.015 亿美元。